Bioharvest Sciences Inc. revenue by segment BHST
Annual
Quarterly
Bioharvest Sciences Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was North America1 at $30.6 million, 89% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
|---|---|---|
| Revenue |
35
|
25
|
| North America1 |
31
+32.9%
share 88.6%
|
23
share 91.4%
|
| Israel |
4
+80.2%
share 11.4%
|
2
share 8.6%
|
| Cdmo Services |
2
+566.0%
share 5.4%
|
0
share 1.1%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1723464
- Former names
- CANNA-V-CELL SCIENCES INC. (until Apr 21, 2020); Midnight Star Ventures Corp. (until Oct 15, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.